Clinical Pathway Management Applied to the Vaginal Delivery for Puerperants with Group B Streptococcal Infection and Term Premature Rupture of Membranes
Chen ZHANG,Shu-fang CHEN,Jun QIU,Qian ZHOU
DOI: https://doi.org/10.3969/j.issn.1007-9572.2017.05.y03
2017-01-01
Chinese General Practice
Abstract:Objective To evaluate the effect of clinical pathway management applied to the vaginal delivery for puerperants with group B streptococcal(GBS) infection and term premature rupture of membranes(TPROM).Methods The enrolled participants were 311 hospitalized puerperants who were diagnosed with GBS and TPROM in International Peace Maternity & Child Health Hospital,Shanghai Jiao Tong University School of Medicine from June 2011 to December 2015.Among them,those who were admitted between June 2011 and June 2014(clinical pathway management was implemented initiatively in the hospital in this period) and did not choose clinical pathway management after having been informed were assigned to the control group,and those who were admitted between July 2014 and December 2015(clinical pathway management was formally implemented in the hospital in this period) and chosen clinical pathway management after having been informed were assigned to the clinical pathway group.Comparison age, parity,period between premature rupture of membranes and start of delivery, times of manual examination of the vaginal, analgesia delivery, the use of antibiotics, abortion, hospitalization expenses and length of stay, maternal and neonatal adverse outcomes incidence between the two groups.Results There were no significant differences between the two groups in terms of age,parity,period between premature rupture of membranes and start of delivery,times of manual examination of the vagina,rate of using analgesics for delivery,proportion of using antibiotics between the period of after 38 weeks of gestation and start of delivery,and induction rate(P>0.05).The median value of hospitalization expenses in the control group was much higher than that in the clinical pathway group(¥4 964.7 vs. ¥4 336.7,u=-3.100,P=0.002),two groups had no differences in length of stay(u=-0.960,P=0.336).The control group had significantly higher maternal infection rate than the clinical pathway group(7.7% vs.2.4%,χ2=4.104,P=0.043).However,when it comes to the rate of neonatal infection,ratio of neonatal hyperbilirubinemia,and proportion of neonates with Apgar scores less than 7,no such differences were detected(χ2=0.143,0.041,0.164,P=0.708,0.840,0.694).Conclusion Clinical pathway management has active effect on the puerperants with GBS infection combined with TPROM in respect to decreasing the hospitalization expenses and reducing the maternal infection rate.